Navigation Links
Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100
Date:1/8/2016

MILPITAS, Calif., Jan. 8, 2016 /PRNewswire/ -- Protagonist Therapeutics, Inc., a company developing novel, orally-stable peptide therapeutics for gastrointestinal (GI) diseases, today announced that the company has initiated treatment of subjects with its lead drug candidate, PTG-100, in a Phase 1 clinical study. Protagonist is developing PTG-100, an orally-stable alpha-4-beta-7 integrin-specific peptide antagonist, as a potential treatment for patients with inflammatory bowel disease (IBD).

"IBD is a chronic inflammatory disease of the gastro-intestinal tract where there is significant need for improved targeted therapies," said Richard Shames, M.D., Chief Medical Officer at Protagonist. "PTG-100 is the only oral alpha-4-beta-7 specific antagonist currently in development, a target that is clinically validated for IBD by the approval of injectable antibody drugs."

"The initiation of the first human study of PTG-100 is an important milestone for Protagonist, marking our evolution from a research-focused company to one engaged in the clinical development of its own products," said Dinesh Patel, Ph.D., Protagonist President and Chief Executive Officer. "PTG-100 is the first of several orally stable peptides in the Protagonist pipeline. We look forward to applying the lessons we learn from this compound's early development to our other programs."

The Phase 1 study, which is being conducted in Australia, is a randomized, double-blind, placebo-controlled, dose-escalation trial in 70 normal healthy volunteers. The first part of the study consists of single-ascending doses of PTG-100 in 40 volunteers. The second part of the study will involve the administration of PTG-100 over 14 consecutive days in 30 additional volunteers. Primary endpoints for the study are safety and tolerability of PTG-100. Secondary endpoints are the identification of the maximally tolerated dose and evaluation of pharmacokinetic and pharmacodynamic parameters.

About Protagonist Therapeutics

Protagonist Therapeutics is a U.S.-incorporated biotechnology company engaged in the discovery and development of orally stable peptides as targeted therapies initially for inflammatory bowel disease (IBD) and other gastrointestinal diseases and disorders. The company has an innovative and proprietary technology platform that enables it to develop potent and orally stable peptides for protein-protein interaction (PPI) targets that have been approached largely by injectable antibodies. Oral peptides may lead to a preferred choice for patients, physicians, and payers by virtue of their better convenience and potentially enhanced safety and efficacy in comparison to other therapeutic options. In addition to PTG-100, Protagonist has several other assets in different stages of research and pre-clinical development.

Protagonist is headquartered in Milpitas, California USA with its pre-clinical and clinical staff in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.

Logo - http://photos.prnewswire.com/prnh/20130501/MM06086LOGO

 


'/>"/>
SOURCE Protagonist Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Protagonist Therapeutics Names David Liu Chief Scientific Officer
2. Protagonist Therapeutics Raises $14 Million in Series B Venture Financing
3. Protagonist Therapeutics Closes 2nd Tranche of $18 Million Series B for Advancing Development Candidate to Clinical Trials in 2015
4. Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
5. Protagonist Therapeutics Receives SBIR Funding for Oral IL-23 Receptor Antagonists for Treatment of Inflammatory Bowel Diseases
6. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
7. Novelos Therapeutics Provides Product Pipeline Update
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
9. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
11. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... WINNIPEG, Manitoba (PRWEB) , ... July 10, 2020 ... ... a global medical device company and advanced manufacturing solutions provider today announced that ... Health Canada approval. , The Company has engineered a new 3D-printed swab design ...
(Date:7/10/2020)... ... July 10, 2020 , ... ... with 25 years of experience and more than 12 million guests, unveiled its ... implies, it promotes care and attention in all facets of the operation, safety, ...
(Date:7/10/2020)... ... 09, 2020 , ... The Urgent Care Association (UCA), College of Urgent Care ... present a virtual education on acute flaccid myelitis (AFM), an uncommon but serious condition ... CT on July 14, 2020. , AFM, which is most prevalent in children, ...
Breaking Medicine Technology:
(Date:8/5/2020)... ... August 05, 2020 , ... The Veterinary Cooperative named ... the largest veterinarian-owned purchasing Cooperative in the United States. , Hamele has spent ... gained extensive knowledge and experience in the animal health industry. In her most ...
(Date:8/5/2020)... ... August 04, 2020 , ... ... impairment, has announced the Best Memory Care Facilities in Austin, Texas. The guide ... and amenities. , According to the Alzheimer’s Association , 5.6 million ...
(Date:8/3/2020)... ... August 03, 2020 , ... The ... the White House, Google, Amelia Arena, the Phoenix airport, the Mayo Clinic, Ramstein ... , According to Global Plasma Solutions (GPS), the manufacturers of the system, most ...
(Date:7/31/2020)... ... July 31, 2020 , ... Today Hinge ... an expansion of clinical & technical capabilities to cover the full continuum of ... and joint health solution. , Currently, employers interested in truly solving their ...
(Date:7/22/2020)... ... July 22, 2020 , ... ... Black Lives Matter movement, the world has changed, and there’s no going back. ... healing. While coping mechanisms help us temporarily manage emotional struggles, healing is the ...
Breaking Medicine News(10 mins):